CP4055 205
Laufzeit: 01.01.2010 - 31.12.2014
imported
Kurzfassung
A phase II study of Elacytarabine (CP-4055) plus Idarubicin as second course remission-induction therapy in patients with acute myeloid leukaemia
Laufzeit: 01.01.2010 - 31.12.2014
A phase II study of Elacytarabine (CP-4055) plus Idarubicin as second course remission-induction therapy in patients with acute myeloid leukaemia